Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its third quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 5, 2026. Individuals interested in participating in the call should dial (833) 461-5787 (U.S.) or (585) 542-9983 (international) using conference ID number and event passcode 496523279. To access the webcast, please visit the Investors & Media section of Ironwood's website at ww.

Business Wire • Oct 28, 2026

Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that its Board of Directors appointed Chief Commercial Officer Tammi Gaskins as Chief Executive Officer and a member of the Board of Directors, effective January 1, 2027. On that date Chief Executive Officer Tom McCourt will retire from his current role and will remai.

Business Wire • Oct 16, 2026

Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?

IRWD's Linzess demand remains strong, with a recent pediatric label expansion and pricing changes poised to support third-quarter 2026 growth.

Zacks Investment Research • Oct 7, 2026

Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - Buy

Ironwood Pharmaceuticals is rated Buy, but the investment thesis hinges on apraglutide, not Linzess, due to looming generic competition. IRWD's Linzess cash flow is largely committed to debt and taxes, with generics expected by 2029 and Medicare price cuts impacting margins. Apraglutide's value depends on successful STARS-2 trial results and timely approval, with peak sales modeled conservatively at $456 million.

Seeking Alpha • Oct 7, 2026

PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?

Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.

Zacks Investment Research • Sep 30, 2026

Ironwood Pharmaceuticals (IRWD) is a Top-Ranked Momentum Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Sep 21, 2026

5 Small Drug Stocks Poised to Benefit From a Biotech Recovery

INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.

Zacks Investment Research • Sep 14, 2026

Ironwood: Medicare Is Not The Problem I Thought It Was

I rate Ironwood Pharmaceuticals, Inc. a buy with a $5.25 fair value. LINZESS generated $143.74 per 30 capsules, close to Medicare's $136 price for 2027. The 44% sales increase was mostly pricing-driven, while demand grew only 4% to 5%.

Seeking Alpha • Sep 11, 2026

Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10th at 10:15 a.m. ET. A live webcast of Ironwood's fireside chat will be accessible through the Investors & Media section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood.

Business Wire • Sep 3, 2026

Ironwood Pharmaceuticals: High Dependence On Its Next Trial

Ironwood Pharmaceuticals is a small-cap GI-focused biotech with strong LINZESS sales but looming patent expiry by 2029–2030. IRWD raised LINZESS full-year U.S. net sales guidance to $1.15–$1.2 billion and its own revenue forecast to $460–$485 million. Apraglutide, IRWD's pipeline asset for SBS-IF, showed statistically significant Phase 3 results and is key to future value.

Seeking Alpha • Aug 26, 2026